Все права защищены.
13.55
0.00 (0.00%)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.
Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagonist in phase 3 LUCIDITY for post-bariatric hypoglycemia, with topline data expected Q3 2026. The company maintains a strong cash position [$317M, funding into 2028], supporting key milestones including potential avexitide commercialization.
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026.
Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's direct holdings at the time, reducing his direct position from 3,517,632 to 3,379,465 shares.
There is no data to display
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S (“Gubra”), a company specializing in peptide-based drug discovery and preclinical contract research services. “We are very.
